Loading...
XTSE
SVA
Market cap49mUSD
Jul 28, Last price  
0.21CAD
1D
0.00%
1Q
2.50%
Jan 2017
-31.67%
Name

Sernova Corp

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
11.78%
Rev. gr., 5y
%
Revenues
0k
5,2840080,3040000000000000000
Net income
-32m
L-17.45%
-433,564-1,257,169-3,592,220-2,753,485-1,468,361-1,846,371-2,016,744-2,568,028-2,002,921-2,746,059-2,859,477-2,499,622-2,639,479-3,698,627-3,971,272-5,321,308-6,965,539-24,420,536-38,997,520-32,192,135
CFO
-19m
L-37.72%
-239,101-758,631-2,225,322-1,249,178-574,196-825,729-901,179-1,569,040-1,205,046-1,704,561-2,164,790-2,553,055-2,740,359-3,916,011-4,192,390-3,939,199-6,843,744-14,421,398-30,339,117-18,896,313
Earnings
Sep 15, 2025

Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
IPO date
Apr 15, 1999
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑102015‑10
Income
Revenues
Cost of revenue
31,838
40,947
24,723
Unusual Expense (Income)
NOPBT
(31,838)
(40,947)
(24,723)
NOPBT Margin
Operating Taxes
7
(629)
118
Tax Rate
NOPAT
(31,845)
(40,318)
(24,841)
Net income
(32,192)
-17.45%
(38,998)
59.69%
(24,421)
250.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,960
20,279
BB yield
-6.46%
-9.27%
Debt
Debt current
101
136
140
Long-term debt
1,038
136
412
Deferred revenue
Other long-term liabilities
Net debt
(4,872)
(19,534)
(49,224)
Cash flow
Cash from operating activities
(18,896)
(30,339)
(14,421)
CAPEX
(99)
(329)
Cash from investing activities
11,119
34,781
(46,341)
Cash from financing activities
5,067
503
36,665
FCF
(18,727)
(40,172)
(25,318)
Balance
Cash
6,012
19,806
49,776
Long term investments
Excess cash
6,012
19,806
49,776
Stockholders' equity
(33,680)
(7,179)
31,818
Invested Capital
21,293
19,830
16,066
ROIC
ROCE
257.04%
EV
Common stock shares outstanding
306,954
303,333
273,593
Price
0.25
-67.11%
0.76
-5.00%
0.80
-36.00%
Market cap
76,738
-66.71%
230,533
5.33%
218,875
-28.68%
EV
71,866
210,999
169,650
EBITDA
(31,298)
(40,502)
(24,283)
EV/EBITDA
Interest
32
118
Interest/NOPBT